Diary - News
All news Adocia and Lilly report positive results
Adocia and Eli Lilly and Company announced the successful completion of a preliminary Phase 1 clinical trial evaluating BioChaperone Lispro U200, a concentrated formulation of BioChaperone Lispro, the ultra-rapid formulation of insulin lispro licensed to Lilly. This completed pilot study aimed to determine the potential for bioequivalence of BioChaperone Lispro U200 to BioChaperone Lispro U100 in healthy volunteers.
